The nebulized route of administration of drugs to the lungs may involve antibiotics in cystic fibrosis, bronchodilators in asthma, COPD and cystic fibrosis, and occasionally steroids in asthma and some other conditions. This review concerns the use of the nebulizer to administer bronchodilators in asthma. Such use may occur on a regular basis at home, but more usually is for management of acute episodes of worsening asthma, either self administered by patient or parent in the home or by health professionals in the emergency department (ED) and hospital. Use for acute situations appears to be common and may be especially prevalent in low income communities. The provision of nebulized bronchodilator therapies to manage asthma patients for management of home continues to puzzle. Use of nebulized treatment is accompanied by low levels of metered dose inhaler (MDI) and spacer use in general and in minority patients, 1 particularly inner city children. 2 One study showed that in minority children between the ages of 10 and 13, 48% were prescribed nebulized therapy and this use was not associated with age or severity of the asthma (Clark NM, Prescribed nebulized therapy in urban minority preteens with asthma. Unpublished data). Other studies 2, 3, 4 have shown levels of use ranging from 33% to 71% in children under 12 years of age. A qualitative study of 35 low-income minority adolescents 5 revealed that almost half had nebulizers available at home and there was no significant difference between those with and without nebulizers concerning outcomes related to asthma control.
Use not supported in guidelines
Although nebulizer use is decreasing in some countries, 6 it is still prevalent. The magnitude of use runs counter to asthma guidelines (see for example the Global Initiative for Asthma Guidelines [GINA], 7 the British Guidelines on the Management of Asthma, 8 The Canadian Pediatric Asthma Counsensus Guidelines, 9 and the United States Guidelines for Diagnosis and Treatment of Asthma). 10 Each of these recommends metered dose inhalers in place of nebulizerdelivered therapies. Bateman et al., 11 based on their analysis of asthma guidelines, have indicated that only a small number of pediatric asthma cases, for example, the most severe in acute exacerbation or those who cannot use a metered dose inhaler with spacer (a very small group) should be given nebulizers for self-treatment. The GINA Guidelines specifically note the lack of evidence for any advantage in using the nebulized route of medicine delivery in children, and the higher cost entailed for the patient and/or health system. 7 Boe et al. 12 echo GINA observing that in acute asthma most at-home treatments can be achieved with hand-held inhalers and spacers. The GINA guidelines also stress that it is very unusual for a child to require long-term nebulized therapy.
Wildhaber 13 showed that nebulizers deliver a larger total dose of medicine at a faster rate, but lung deposition at different ages from the two methods (MDI and spacer versus nebulizer) was the same. Colacone 14 showed in a log dose response curve that the equivalent dose ration was 1:6 with lower required dose for clinical result in favor of the MDI with spacer. This, one may speculate, may occur because MDI spacer treatment is given as single doses over a period of time so the effect can be seen and the dose effectively reduced. Perhaps, the great amount of a drug, for example, salbutamol, given in practice by nebulizer may explain greater systemic toxicity 15 and less salubrious outcomes associated with nebulized medicine.
Studies of nebulizer use generally exclude children with life-threatening asthma. However, this event is very rare in children and these patients do not represent the majority presenting for asthma care. One study 7 showed that less than 40% of children arriving at the ED received oxygen at any time during the visit. Only 5% received aminophylline, a marker of more serious disease. Over treating the majority of children with nebulized medicine while waiting for the rare child with life-threatening asthma does not seem reasonable.
The desaturation more frequently observed with nebulized treatment can be severe and lead to unwanted consequences. Duarte 16 et al., for example, showed one-quarter of children treated with oxygendriven nebulizers suffered desaturation during treatment compared to 9% treated with MDI and spacer. It may be that more rapid delivery of a larger dose temporarily overwhelms the respiratory system and leads to an increase in VQ mismatching.
A number of studies have shown that in children with asthma, excluding those 0 through 5 years of age, MDIs with spacers are at minimum as effective as nebulized treatment (see, for example references 2, 4, 17-25). Other studies have shown that nebulized treatment is less effective than treatment by MDI with spacer even in acute situations. For example, Butz 2 et al. found that at-home use of nebulized treatment by inner city children compared to non-users was associated with increased life-time hospitalizations and significantly more hospital admissions and ED visits. This is unlikely to be a causal relationship, more that non-adherence to one aspect of treatment guidelines may be accompanied by other aspects of sub-optimal care. The accumulated empirical evidence, for example, the Cochrane Collaboration review 15 aggregating randomized clinical trial data, clearly shows differences in the two treatment methods for hospitalizations.
Why do Clinicians Continue to Recommend Use?
So, why the continued acceptance of nebulized treatment? Reasons have been posited by several investigators. Barry et al., 26 for example, showed that physicians who recommend nebulized therapy perceive that there is more direct aerolization of medicine into the respiratory system compared to MDIs with spacers. However, this perception has been disproved sufficiently to be mentioned in the GINA Guidelines.
The
Clinician preference may also be associated with perceptions about patient capabilities. For example, the elderly may be thought to have difficulty handling the spacer due to age-related weakness 11 or tremor. In school and clinic settings upkeep and supplies for nebulizers may be cheaper than providing spacers. Another reason for nebulizer preference may be clinicians' misconceptions regarding the efficacy and/or safety of MDIs with spacers. 22 Knowing the facts, however, does not always change practice. Tien et al. 27 surveyed 333 physicians providing ED asthma care to children and found that despite possessing knowledge of the efficacy and safety of MDIs with spacers, only 10% to 21% employed them. The majority believed that MDIs with spacers require more staff supervision. A recent study of 35 EDs showed that 94% used the nebulized route of administering bronchodilators for their adult patients. One-third routinely used nebulizers for children and another third used both methods. 28 Both physicians and nurses perceived that MDIs with spacers, as opposed to nebulizers, required more teaching and administrative time. These perceptions were evident despite studies that have shown MDIs with spacers require less time and equipment to administer, are more cost-effective, and are more portable than nebulizers. 27, 28 Bowton et al. 29 found significant cost savings to an institution when MDIs with spacers were substituted for nebulizers. Further, in a recent Cochrane review of studies involving children 2 years of age and older, MDIs with spacers were shown to result in less time spent in the ED and less tachycardia when compared to nebulization. In older patients, other dangers may arise from the use of nebulizers and precipitation of angina has been reported. 30 
Why do Patients use Nebulizers?
The most frequently heard reason for prescribing nebulizers to patients for use at home is patient preference. Preference has been linked to lack of confidence in the ability to use MDIs with spacers. 31 Physicians'-reported concerns include the perception that their patients will be dissatisfied if nebulized therapy is not given. In a study by Tien el al., 27 MDI with spacer use was described by clinicians as resisted by patients and families. Patients were most likely to express concerns about cost although nebulizers have been shown to require greater expenditure of time and effort on the part of the family. 11 According to Canny, 32 patient resistance to MDIs with spacers can be seen in families' reports that they find it especially hard to help a child 'coordinate' breathing with the device. However, the development of more user-friendly face masks and spacers have made them easier to employ even with the youngest of children.
Madge et al. 33 have shown that despite perceived patient preference, incorrect use of nebulized therapy is significant. Just over 20% of parents in their study admitted that they gave their children nebulized bronchodilators more frequently than prescribed. Butz et al., 34 showed that education in the proper use of nebulized therapy had no effect on asthma severity in children or on their subsequent health care use. On the other hand, Dewar 21 showed MDI with spacer use, including continuous patient training, reduced hospital admission rates compared to nebulizer treatment. They suggested such training may have been the reason for differences observed.
In addition to physician perceptions and patient concerns is the problem of the condition of the nebulizing device itself. Madge 33 et al. found that less than 10% of users of nebulizers had ever had their device serviced. Cleanliness is an issue as most devices require attention on a regular basis. Most EDs use disposable nebulizers and lack of service is not an issue although cost of disposable items may be. In some systems, for example, the United States, incentives to medical device suppliers and insurance coverage usually results in well-maintained nebulizers in emergency facilities. However, the cost of upkeep, particularly in low-income groups, can be a barrier to families using nebulizers at home. Studies have shown that families do not routinely provide the needed level of care of nebulizers in line with manufacturers' recommendations. 35 Devices are often transported from place to place based on a child's daily routine. One of the authors has observed nebulizers in schools where counselors were asked by parents to administer medicine to children (Unpublished data). In these cases, the devices examined clearly did not meet required standards of cleanliness or condition.
What will change nebulizer use?
Continued use of nebulized medications is likely due to cost factors, individual misconceptions, and practitioner routines. What will it take to improve the picture of medicine delivery for patients with asthma? All available guidelines [7] [8] [9] [10] stress the importance of effective use of medicine in asthma control. If a delivery route is difficult to keep clean or functioning optimally, reduces the likelihood of effective administration, and underperforms in producing outcomes, what can be done to discourage its use as a routine form of medicine provision? Part of the answer, in some health systems, may rest with reducing cost barriers for MDI spacer use. Certainly resolution includes more targeted, ongoing, and emphatic asthma education for clinicians who treat those with asthma, aiding them to understand the deficiencies of nebulizers (even, perhaps, as shown by Hendeles 24 , taking a delivery approach and allowing pharmacists and respiratory therapists to automatically convert prescriptions for a nebulizer to an MDI and spacer). Several investigators have outlined means to achieve significant change. For example, one study 36 showed increased use by hospital based clinicians of MDIs with spacers from 10% to 80% with an extensive, intensive and facility-wide approach including computerized order sets. Clinicians' tendency to use nebulizers to administer medicine fortifies patient beliefs and behaviors that are not optimum. No doubt, clinicians need to be encouraged not to assume patients will prefer to use nebulizers and patient education is clearly needed. 37 Patient preference is an important consideration in treatment. However, uninformed preference reduces therapeutic efficacy. Education can help patients see the importance of using effective delivery devices, ones that will actually change asthma outcomes. Research seems warranted to identify in a very precise way the small number of patients and situations that require at-home use of nebulized therapies.
Although change in clinical behavior may be occurring, it is slow in coming. 38 Asthma treatment continues to be hampered by a practice that doesn't deliver in the way that patients deserve.
